TABLE II.
First primary cancerb | Males (n = 9,891)
|
Females (n =11,426)
|
Overall (n = 21,317)
|
||||||
---|---|---|---|---|---|---|---|---|---|
OBS | SIR | 95%CI | OBS | SIR | 95%CI | OBS | SIR | 95%CI | |
All cancers combined | 1549 | 0.92 | 0.87–0.96 | 1822 | 0.94 | 0.90–0.98 | 3371 | 0.93 | 0.90–0.96 |
MN of buccal and pharynx | 39 | 0.70 | 0.50–0.96 | 25 | 0.80 | 0.52–1.19 | 64 | 0.74 | 0.57–0.94 |
MN of colon and rectum | 157 | 0.88 | 0.74–1.02 | 225 | 1.08 | 0.94–1.23 | 382 | 0.98 | 0.89–1.09 |
MN of other digestive organs and peritoneum | 135 | 1.00 | 0.84–1.19 | 111 | 0.89 | 0.73–1.07 | 246 | 0.95 | 0.83–1.08 |
MN of stomach | 40 | 1.23 | 0.88–1.68 | 18 | 0.79 | 0.47–1.25 | 58 | 1.05 | 0.80–1.36 |
MN of respiratory and intrathoracic organs | 344 | 1.16 | 1.04–1.29 | 354 | 1.31 | 1.18–1.45 | 698 | 1.23 | 1.14–1.33 |
MN of breast | 6 | 1.81 | 0.66–3.93 | 500 | 0.80 | 0.73–0.87 | 506 | 0.80 | 0.73–0.88 |
MN of female genital organs | 0 | 235 | 0.90 | 0.79–1.02 | 235 | 0.90 | 0.79–1.02 | ||
MN of the uterus | 0 | 105 | 0.77 | 0.63–0.93 | 105 | 0.77 | 0.63–0.93 | ||
MN of the ovary | 0 | 70 | 0.93 | 0.72–1.17 | 70 | 0.93 | 0.72–1.17 | ||
MN of male genital organs | 436 | 0.82 | 0.75–0.90 | 0 | 436 | 0.82 | 0.75–0.90 | ||
MN of prostate | 432 | 0.83 | 0.76–0.92 | 0 | 432 | 0.83 | 0.76–0.92 | ||
MN of urinary organs | 153 | 0.94 | 0.80–1.11 | 106 | 1.27 | 1.01–1.53 | 259 | 1.05 | 0.93–1.19 |
MN of thyroid and other endocrine organs | 7 | 0.56 | 0.22–1.15 | 14 | 0.43 | 0.23–0.72 | 21 | 0.46 | 0.29–0.71 |
MN of other solid cancers | 96 | 0.76 | 0.62–0.93 | 68 | 0.70 | 0.54–0.88 | 164 | 0.73 | 0.62–0.85 |
MN of the brain | 20 | 0.82 | 0.50–1.26 | 19 | 0.80 | 0.48–1.25 | 39 | 0.81 | 0.58–1.11 |
MN of lymphatic and hematopoietic organs | 131 | 0.88 | 0.73–1.04 | 139 | 0.93 | 0.78–1.09 | 270 | 0.90 | 0.80–1.01 |
Ill-specified and residual | 45 | 1.11 | 0.81–1.49 | 45 | 0.89 | 0.65–1.19 | 90 | 0.99 | 0.80–1.22 |
MN, malignant neoplasm; OBS, observed number of cases; SIR, standardized incidence ratio; CI, confidence interval.
The analysis included cases of first primary incident cancers identified using the nine state cancer registries (Connecticut, New York, Massachusetts, Rhode Island, Indiana, California, Texas, Florida, and North Carolina); split any gaps in the residence history at the midpoint and as signed the first half of the gap to the earlier state and the second half of the gap to the later state; and limited person-time at risk to the initial risk period (i.e.,person-time at risk was censored at the date the worker was first known to be living outside the catchment).
Results for all major cancer sites and selected minor cancer sites. Specific ICD-O-3 codes associated with each grouping are listed in Supplemental File, Table SII.